<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen56">
		<pathogen_name>Rabies virus</pathogen_name>
		<taxon_id>11292</taxon_id>
		<pathogenesis refs="reference736">The virus is usually present in the nerves and saliva of a symptomatic rabid animal. The route of infection is usually by a bite. The infected animal is often exceptionally aggressive. Transmission may also occur via an aerosol through mucous membranes. After a typical human infection by bite, the virus enters the peripheral nervous system. It then travels along the nerves towards the central nervous system. Once the virus reaches the brain, it rapidly causes encephalitis. Rabies may also inflame the spinal cord producing myelitis (Wiki: Rabies).</pathogenesis>
		<disease_name>Rabies</disease_name>
		<protective_immunity refs=""></protective_immunity>
		<host_range refs="reference736">Most animals can be infected by the virus and can transmit the disease to humans. Infected bats, monkeys, raccoons, foxes, skunks, cattle, wolves, dogs or cats provide the greatest risk to humans. Rabies may also spread through exposure to infected domestic farm animals, groundhogs, weasels and other wild carnivores. Rodents (mice, squirrels etc) are seldom infected (Wiki: Rabies).</host_range>
		<introduction refs="reference736">Rabies virus is a member of the Lyssavirus genus. The virus has a bullet-like shape with a length of about 180 nm and a cross-sectional diameter of about 75 nm (Wiki: Rabies).</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine4099">
		<vaccine_name>AdC68- rabies virus glycoprotein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004630</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>[Ref3084:Xiang et al., 2014]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3084">Chimpanzee adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein (Xiang et al., 2014).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1767" gene_id="gene647">
			<type>Recombinant vector construction</type>
			<description refs="reference2162">A plasmid vector, termed pSG5rab.gp, that expresses the rabies virus glycoprotein under the control of an SV40 early promoter (Xiang et al., 1994).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1861" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3084">An AdC vector control was used at 10^11 vp. A commercially available human diploid cell rabies vaccine (HDCV), used intramuscularly at the recommended dose for pre-exposure vaccination, was included. The AdC vector vaccine was only given once, and the HDCV was given three times on days −41, −27 and −20 in relation to the AdC vaccine (Xiang et al., 2014).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3084">The immunization resulted in sustained titers of rabies virus neutralizing antibodies and protection against a lethal rabies virus challenge infection in a non-human primate model (Xiang et al., 2014).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3084">Animals were challenged at 18 weeks after the last vaccine dose with ~10^6.4 (MICLD)50/ml as calculated via the Spearman–Kaerber method, of a virulent street strain of canine rabies virus (Xiang et al., 2014).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4111">
		<vaccine_name>ALVAC-rabies</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004639</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4213">
		<vaccine_name>ALVAC-RV</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004728</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3096">A non-adjuvanted feline rabies vaccine developed using the canarypoxvirus vector (Jas et al., 2012).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1857" host_id="host37">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3096">Seronegative cats were vaccinated at 12 weeks of age and received a booster vaccination one year later (Jas et al., 2012).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000287</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3096">This vaccination regimen induced a strong and sustained antibody response, and all vaccinated animals were protected against virulent rabies challenge carried out 3 years after vaccination (Jas et al., 2012).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="">The cats were challenged by inoculation of 1 mL of rabies virus in the neck muscles (0.5 mL on the left and right side of the spine). The inoculum was a homogenate of salivary glands of foxes and each cat received 10^7.7 mouse Lethal Dose 50, the equivalent of 10^6.8 CCID50.</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4124">
		<vaccine_name>BV-RVG/RVG</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004651</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3106">Recombinant baculovirus (BV-RVG/RVG) was pseudotyped with the rabies virus glycoprotein (RVG) and also simultaneously expressed another RVG under the control of the immediate early CMV promoter (Wu et al., 2014).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1764" gene_id="gene1033">
			<type>Recombinant protein preparation</type>
			<description refs="reference3106">The recombinant baculovirus (BV-RVG/RVG) was pseudotyped with the rabies virus glycoprotein (RVG) and also simultaneously expressed another RVG under the control of the immediate early CMV promoter (Wu et al., 2014).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1858" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3106">Mice were immunized intramuscularly with 1 × 10^8 IFU of BV-VSVG/EGFP, BVRVG/EGFP, or BV-RVG/RVG at 3-week interval (Wu et al., 2014).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3106">Mice immunized with BV-RVG/RVG developed higher levels of virus-neutralizing antibodies, and conferred 100% protection against rabies viral challenge (Wu et al., 2014).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3106">Mice were challenged intracerebrally with 50 mouse 50% lethal doses (50 LD50) of rabies virus CVS-24 (Wu et al., 2014).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1656">
		<vaccine_name>Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus-Rabies Modified Live &amp; Killed Virus Vaccine (USDA: 13G9.20)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Intervet Inc.</manufacturer>
		<vo_id>VO_0002111</vo_id>
		<type>Live, attenuated vaccine; Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1675">
		<vaccine_name>Canine Distemper-Adenovirus Type 2-Parvovirus-Rabies Modified Live &amp; Killed Virus Vaccine (USDA: 13H9.20)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Intervet Inc.</manufacturer>
		<vo_id>VO_0002112</vo_id>
		<type>Live, attenuated vaccine; Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1882">
		<vaccine_name>Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Modified Live &amp; Killed Virus, Modified Live Chlamydia Vaccine (USDA: 1619.20)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Merial, Inc.</manufacturer>
		<vo_id>VO_0001868</vo_id>
		<type>Live, attenuated vaccine; Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1887">
		<vaccine_name>Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Modified Live Virus and Chlamydia, Canarypox Vector Vaccine (USDA: 1619.R1)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Merial, Inc.</manufacturer>
		<vo_id>VO_0001869</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1891">
		<vaccine_name>Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Modified Live &amp; Killed Virus Vaccine (USDA: 16T9.20)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Intervet Inc., Merial, Inc.</manufacturer>
		<vo_id>VO_0001870</vo_id>
		<type>Live, attenuated vaccine; Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1895">
		<vaccine_name>Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Modified Live Virus, Canarypox Vector Vaccine (USDA: 16T9.R0)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Merial, Inc.</manufacturer>
		<vo_id>VO_0001871</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine341">
		<vaccine_name>Imovax Rabies</vaccine_name>
		<proper_name>Rabies Vaccine</proper_name>
		<brand_name>Imovax</brand_name>
		<manufacturer>Sanofi Pasteur, SA</manufacturer>
		<vo_id>VO_0000063</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed>USA (License #1724)</location_licensed>
		<description refs="reference734">Imovax is a sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA. This vaccine must only be used intramuscularly and as a single dose vial (FDA: Imovax).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="reference734">The vaccine should be stored in the refrigerator at 2°C to 8°C (35°F to 46°F). Do not freeze (FDA: Imovax).</storage>
		<virulence refs=""></virulence>
		<preparation refs="reference734">The virus strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA, is harvested from infected human diploid cells (MRC-5 strain), concentrated by ultrafiltration and is inactivated by beta-propiolactone. One dose of reconstituted vaccine contains less than 100 mg albumin, less than 150 μg neomycin sulfate and 20 μg of phenol red indicator.  The vaccine contains no preservative or stabilizer (FDA: Imovax).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">Strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA.</antigen>
		<host_response host_response_id="host_response444" host_id="host2">
			<immune_response refs="reference734">Seroconversion was often obtained with only one dose. With two doses one month apart, 100% of the recipients developed specific antibody (FDA: Imovax).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference734">Most common side effects reported in clinical studies included: injection site reactions, headache, nausea, abdominal pain, muscle aches and dizziness (FDA: Imovax).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine404">
		<vaccine_name>Purevax Feline Rabies</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Purevax Feline Rabies</brand_name>
		<manufacturer>Merial</manufacturer>
		<vo_id>VO_0000871</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="">Canarypox virus-vectored vaccine</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine342">
		<vaccine_name>RabAvert</vaccine_name>
		<proper_name>Rabies Vaccine</proper_name>
		<brand_name>RabAvert</brand_name>
		<manufacturer>Novartis Vaccines and Diagnostics</manufacturer>
		<vo_id>VO_0000094</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed>USA (License #1754)</location_licensed>
		<description refs="">A sterile freeze-dried vaccine obtained by growing the fixed-virus strain Flury LEP in primary cultures of chicken fibroblasts.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="reference776">RabAvert should be stored protected from light at 2°C to 8°C (36°F to 46°F) (Rabavert).</storage>
		<virulence refs=""></virulence>
		<preparation refs="reference776">The strain Flury LEP was obtained from American Type Culture Collection as the 59th egg passage. The growth medium for propagation of the virus is a synthetic cell culture medium with the addition of human albumin, polygeline (processed bovine gelatin) and antibiotics. The virus is inactivated with beta-propiolactone, and further processed by zonal centrifugation in a sucrose density-gradient. The vaccine is lyophilized after addition of a stabilizer solution, which consists of buffered polygeline and potassium glutamate (Rabavert).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response447" host_id="host2">
			<immune_response refs="reference776">When administered according to the recommended immunization schedule (days 0, 7, 21), 100% of subjects attained a protective titer (Rabavert).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference776">The most common side effects reported are: injection site reactions (redness, itching, and swelling), fever, and swollen lymph nodes (Rabavert).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine816">
		<vaccine_name>Rabies DNA Vaccine encoding Rabies virus Glycoprotein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011553</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pgp.LAMP-1 [Ref1236:Kaur et al., 2010]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering281" gene_id="gene647">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response575" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference1236">For the intramuscular route, mice were vaccinated with 100 µg of endotoxin-free pDNA in 200 µl of PBS/animal in the anterior quadriceps muscle, in the individual groups (DNA vaccine or vector control), 3 times at 3-wk intervals. Control mice were immunized with PBS only (Kaur et al., 2010).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1236">DNA vaccine imparted partial protection (60%) against challenge with 20 LD(50) of the challenge virus standard (CVS) strain of rabies virus (Kaur et al., 2010).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1236">For challenge studies, immunized mice were inoculated intracerebrally with 20 LD50 of the CVS strain of rabies virus 21 d after the last immunization. The challenged mice were observed for 18 d for symptoms indicative of rabies virus infection (Kaur et al., 2010).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine2115">
		<vaccine_name>Rabies Killed Virus Vaccine (USDA: 1905.20)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Wyeth, Intervet Inc., Merial, Inc.</manufacturer>
		<vo_id>VO_0001760</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine2116">
		<vaccine_name>Rabies Killed Virus Vaccine (USDA: 1905.21)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Wyeth, Intervet Inc., Merial, Inc.</manufacturer>
		<vo_id>VO_0001761</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine2117">
		<vaccine_name>Rabies Killed Virus Vaccine (USDA: 1905.22)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Intervet Inc.</manufacturer>
		<vo_id>VO_0001762</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine2118">
		<vaccine_name>Rabies Killed Virus Vaccine (USDA: 1905.23)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Wyeth, Intervet Inc., Merial, Inc.</manufacturer>
		<vo_id>VO_0001763</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine2119">
		<vaccine_name>Rabies Killed Virus Vaccine (USDA: 1905.24)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Pfizer, Inc., Merial, Inc.</manufacturer>
		<vo_id>VO_0001764</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3010">
		<vaccine_name>Rabies Killed Virus Vaccine-Ehrlichia Risticii Bacterin (USDA: 4905.20)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Merial, Inc.</manufacturer>
		<vo_id>VO_0002289</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine2113">
		<vaccine_name>Rabies Live Canarypox Vector Vaccine (USDA: 1901.R1)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Merial, Inc.</manufacturer>
		<vo_id>VO_0001765</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine2114">
		<vaccine_name>Rabies Live Canarypox Vector Vaccine (USDA: 1901.R6)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Merial, Inc.</manufacturer>
		<vo_id>VO_0001766</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine2112">
		<vaccine_name>Rabies Live Vaccinia Vector Vaccine (USDA: 1901.R0)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Merial, Inc.</manufacturer>
		<vo_id>VO_0001767</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine340">
		<vaccine_name>Rabies Vaccine Adsorbed (RVA)</vaccine_name>
		<proper_name>Rabies Vaccine Adsorbed</proper_name>
		<brand_name>None</brand_name>
		<manufacturer>BioPort Corp</manufacturer>
		<vo_id>VO_0000095</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs="reference733">BioPort's Rabies Vaccine is effective for pre- and post-exposure indications, and is administered intramuscularly (not intradermally). However, this vaccine is no longer available for rabies postexposure or pre-exposure prophylaxis, and intradermal pre-exposure prophylaxis is no longer recommended because it is not available in the United States (Manning et al., 2008).</description>
		<adjuvant refs="">Aluminum phosphate</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="">Rabies Vaccine Adsorbed (RVA) is an aqueous formulation of rabies virus cultured in diploid fetal rhesus lung (FRhL-2) cells, inactivated with beta-propiolactone (BPL), and adsorbed on aluminum phosphate adjuvant. The vaccine is prepared from the Kissling strain of Challenge Virus Standard (CVS) rabies virus adapted to fetal rhesus lung diploid cell culture. The inactivated virus is concentrated by adsorption onto aluminum phosphate adjuvant.</preparation>
		<route refs=""></route>
		<antigen refs="">Inactivated Kissling strain of Challenge Virus Standard (CVS) rabies virus.</antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine818">
		<vaccine_name>Rabies vaccine rVac-N</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011555</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Vaccinia virus [Ref1237:Fujii et al., 1994]</vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering284" gene_id="gene648">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response577" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">A/J</host_strain>
			<vaccination_protocol refs="reference1237">4-week-old mice were injected intraperitoneally (i.p.) on days 0 and 14 with 10^7 p.f.u, of the recombinant viruses. Control mice received equal doses of vaccinia virus recombinant vSC8  that contained no rabies virus sequences (Fujii et al., 1994).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1237">92 % of mice given rVac-N (i.e. one animal succumbed b u t still had a prolonged lifespan) survived the challenge with rabies virus (Fujii et al., 1994).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1237">On day 21, the mice were challenged by footpad injection with 0.02 ml (20 MFPLDs0 , where MFPLDs0 represents mouse footpad 50% lethal dose) of the 1088 strain (Fujii et al., 1994).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3556">
		<vaccine_name>Rabies virus DNA vaccine encoding the ERA glycoprotein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004372</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCMV4 [Ref2380:Lodmell et al., 2000]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2380">monophosphoryl lipid A(MPL) (Lodmell et al., 2000)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1096" gene_id="gene1229">
			<type>DNA vaccine construction</type>
			<description refs="reference2380">This DNA vaccine expressed the full-length cDNA of the ERA rabies virus glycoprotein  (Lodmell et al., 2000).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1396" host_id="host3">
			<immune_response refs="reference2380">Neutralizing antibody titers were enhanced following primary i.m. vaccination with DNA and MPL® (Lodmell et al., 2000).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2380">After virus challenge, in the group of mice that were vaccinated with MPL, 4 of 6 mice with individual neutralizing antibody titers of 1:10 survived viral challenge. In addition, in the group of mice that did not receive MPL, 100% of the mice survived viral challenge after their second booster  (Lodmell et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3555">
		<vaccine_name>Rabies virus DNA vaccine pCMV-intA-rabies encoding glycoprotein G</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004371</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCMV-intA [Ref2268:Osorio et al., 1999]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1095" gene_id="gene647">
			<type>DNA vaccine construction</type>
			<description refs="reference2268">Vector pCMV-intA expressed the rabies glycoprotein G (Osorio et al., 1999).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1394" host_id="host37">
			<immune_response refs="reference2268">Neutralizing antibody responses following DNA vaccination lasted at least nine months with high levels of RVNA in all i.m.-vaccinated dogs, and eleven of twelve i.d.-vaccinated cats. This suggests that a DNA rabies vaccine can induce durable and protective immune responses against rabies infection in companion animals (Osorio et al., 1999).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2268">The geometric mean RVNA titer in the combined intradermal cat groups at day 289 was 341, a titer that correlates with solid protection against rabies challenge. Thus, it is reasonable to conclude that the high neutralization activity observed in the studies described here will afford protection against challenge, even though a challenge study was not performed (Osorio et al., 1999).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3375">
		<vaccine_name>Rabies virus DNA vaccine pSG5rab.gp</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004326</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pSG5  [Ref2162:Xiang et al., 1994]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering923" gene_id="gene1229">
			<type>DNA vaccine construction</type>
			<description refs="reference2162">Vector pSG5 expressed the rabies glycoprotein (ERA strain)  (Xiang et al., 1994).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1187" host_id="host3">
			<immune_response refs="reference2162">Mice immunized intramuscularly with the pSG5rab.gp vector developed rabies virus glycoprotein-specific cytolytic T cells, lymphokinesecreting T helper cells of the TH1 subset, and rabies virus-neutralizing antibodies (Xiang et al., 1994).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2162">Mice vaccinated with the pSG5rab.gp vector were fully protected against a subsequent challenge with rabies virus (Xiang et al., 1994).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3187">
		<vaccine_name>Rabies virus glycoprotein G mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0002991</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering715" gene_id="gene1033">
			<type>Gene mutation</type>
			<description refs="reference1977">This glycoprotein G mutant is from Rabies virus (Wu et al., 2011).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1011" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1977">A glycoprotein G mutant is attenuated in mice (Wu et al., 2011).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1977">A glycoprotein G mutant induces protection in mice from challenge with wild type rabies virus (Wu et al., 2011).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response1012" host_id="host16">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1977">A glycoprotein G mutant is attenuated in hamsters (Wu et al., 2011).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1977">A glycoprotein G mutant induces significant protection in hamsters from challenge with wild type rabies virus (Wu et al., 2011).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3188">
		<vaccine_name>Rabies virus P protein mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0002992</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intracranial immunization</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intracranial immunization</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering716" gene_id="gene944">
			<type>Gene mutation</type>
			<description refs="reference1803">This P protein mutant is from rabies virus (Morimoto et al., 2005).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1013" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1803">A P protein mutant is attenuated in mice (Morimoto et al., 2005).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1803">A P protein mutant induces protection in mice from challenge with wild type rabies virus (Morimoto et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine403">
		<vaccine_name>Raboral</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Raboral</brand_name>
		<manufacturer>Merial</manufacturer>
		<vo_id>VO_0000928</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference828 reference829 reference830">Vaccinia virus recombinant(Brochier et al., 1991)(Mackowiak et al., 1999)(Rupprecht et al., 2004)</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4178">
		<vaccine_name>RCN-rabies-G</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004693</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3215">Recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 2003).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1763" gene_id="gene1033">
			<type>Recombinant vector construction</type>
			<description refs="reference2268">A recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G)  (Osorio et al., 1999).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1856" host_id="host37">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3215">The cats were vaccinated by the oral (PO), intranasal (IN), conjunctival (CO) or intranasal/conjunctival (IN/CO) route (dose: 10 plaque forming units or PFU) (Osorio et al., 2003).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000287</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3215">The RVNA titers remained high when measured at six months post-vaccination, demonstrating that the recombinant vaccine administered via these routes is very efficient at inducing long-lasting immunity (Osorio et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3215">Because of humanitarian concerns, we did not perform rabies virus challenge on these cats. However, RVNA titers of 1:5 (0.69 log10) or greater in humans have been correlated with vaccine protection (Smith et al., 1996). Thus, it is reasonable to surmise that the high RVNA titers observed in the immunized cats could provide protection against challenge (Osorio et al., 2003).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4253">
		<vaccine_name>rLSDV-Rabies-gP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004762</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3278">Using the rabies virus glycoprotein (RG) as a model antigen, the recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) was able to express RG (Aspden et al., 2003).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1765" gene_id="gene1033">
			<type>Recombinant vector construction</type>
			<description refs="reference3278">Recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) (Aspden et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1859" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3278">NMRI mice (3–4 weeks, n=30 per group; South African Vaccine Producers) were inoculated intramuscularly on days 0 and 14 with either PBS (50 μl), rLSDV-RG (5×10^4 f.f.u. ml−1 in 50 μl), LSDV-wt (5×10^4 f.f.u. ml−1 in 50 μl) or Verorab (1/10 human equivalent dose in 50 μl) (Aspden et al., 2003).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3278">Mice immunized with rLSDV-RG elicited levels of RV-specific cellular immunity (T-cell proliferation) comparable with those of mice immunized with a commercial inactivated rabies vaccine (Verorab; Pasteur Merieux). Most importantly, mice immunized with rLSDV-RG were protected from an aggressive intracranial rabies virus challenge (Aspden et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3278">On day 21, ten mice from each group were challenged intracranially with 8×10^−1 LD50, 8×10^−2 LD50 or 8×10^−3 LD50 dilution of live rabies virus (Aspden et al., 2003).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4257">
		<vaccine_name>rORFV-RabG</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004766</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3281">Orf virus (ORFV) recombinant, D1701-V-RabG, expressing the rabies virus (RABV) glycoprotein (Amann et al., 2013).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1766" gene_id="gene648">
			<type>Recombinant vector construction</type>
			<description refs="reference3281">Orf virus (ORFV) recombinant, D1701-V-RabG, expressing the rabies virus (RABV) glycoprotein that is correctly presented on the surface of infected cells without the need of replication or production of infectious recombinant virus(Amann et al., 2013).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1860" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3281">Mice were i.m. immunized once, twice, or thrice with 10^7 PFU of D1701-V-RabG in 2-week intervals. Two other groups were vaccinated three times with 10^6 PFU either i.m. or s.c (Amann et al., 2013).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3281">All i.m. immunized animals, receiving one, two, or three inoculations of 10^7 PFU or three doses of 10^6 PFU, were completely protected, whereas 4 out of the 5 s.c. immunized animals survived the challenge. The D1701-V-RabG-immunized and protected mice did not reveal any harmful reaction, loss of body weight, or RABV-specific clinical signs (Amann et al., 2013).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3281">Two weeks after the last immunization, all mice were i.c. challenged with 3,000 mouse i.c. LD50 of the highly pathogenic RABV CVS-11 strain (Amann et al., 2013).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<gene gene_id="gene647">
        <gene_name>G</gene_name>
        <strain>Rabies virus</strain>
        <vo_id>VO_0011231</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>56384945</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279337</xrefs>
        <taxonomy_id>11292</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>glycoprotein</protein_name>
        <protein_pi>7.66</protein_pi>
        <protein_weight>55317.81</protein_weight>
        <protein_length>578</protein_length>
        <protein_note>Rhabdovirus spike glycoprotein; pfam00974</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAV85905.1 glycoprotein [Rabies lyssavirus]
MVPQALLFVPFLGFSLCFGKFPIYTIPDKLGPWSPIDIHHLSCPNNLVVEDEGCTNLSGFSYLELKVGHI
SAIKVNGFTCTGVVTEAETYTNFVGYVTTTFKRKHFRPTPDACRAAYNWKTAGDPRYEESLQNPYPDYQW
LRTVRTTKESLVIISPSAADLDPYDKSLHSRVFPSGKCSGITVSSVYCSTNHDYTIWMPENPRQGMSCDI
FTNSRGKRASKERKTCGFVDERGLYKSLRGSCKLKLCGVLGLRLMDGTWVAMQTSNETKWCSPDQLVNLH
DFHSDEIEHLVVEELVKKREECLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIINKTLMEAEAHYKS
VRTWNEIVPSKGCLRVEGRCHPHVNGVFFNGIILGPDGHVLIPEMQSSLLQQHMELLESSVIPLMHPLAD
PSTVFKEGDEAEDFVEVHFPDVHKKVSEVDLGLPNWGEYVLLSAGTLIALMLIIFLMICRRRVNRPESTQ
RSLRGTEMKVSVTPQSGKFKSSWESYKSGDEARL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A DNA vaccine based on lysosome-targeted glycoprotein of the rabies virus was evaluated in BALB/c mice. It imparted partial protection (60%) against challenge with 20 LD(50) of the challenge virus standard (CVS) strain of rabies virus [Ref1236:Kaur et al., 2010].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1229">
        <gene_name>glycoprotein</gene_name>
        <strain>Rabies virus ERA</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>156446052</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:110007</xrefs>
        <taxonomy_id>11292</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>glycoprotein</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>505</protein_length>
        <protein_note>laboratory stock</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>gi|156446052|gb|ABK27940.2| glycoprotein [Rabies virus]
KFPIYTIPDKLGPWSPIDIHHLSCPNNLVVEDEGCTNLSGFSYMELKVGYILAIKMNGFTCTGVVTEAET
YTNFVGYVTTTFKRKHFRPTPDACRAAYNWKMAGDPRYEESLHNPYPDYRWLRTVKTTKESLVIISPSVA
DLDPYDRSLHSRVFPSGKCSGVAVSSTYCSTNHDYTIWMPENPRLGMSCDIFTNSRGKRASKGSETCGFV
DERGLYKSLKGACKLKLCGVLGLRLMDGTWVAMQTSNETKWCPPDQLVNLHDFRSDEIEHLVVEELVRKR
EECLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIFNKTLMEADAHYKSVRTWNEILPSKGCLRVGGR
CHPHVNGVFFNGIILGPDGNVLIPEMQSSLLQQHMELLESSVIPLVHPLADPSTVFKDGDEAEDFVEVHL
PDVHNQVSGVDLGLPNWGKYVLLSAGALTALMLIIFLMTCCRRVNRSEPTQHNLRGTGREVSVTPQSGKI
ISSWESHKSGGETRL</protein_sequence>
        <phi_function>Other</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1033">
        <gene_name>Glycoprotein G</gene_name>
        <strain>Rabies virus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1489856</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9627201</ncbi_protein_id>
        <gene_locus_tag>RABVgp4</gene_locus_tag>
        <gene_refseq>M13215</gene_refseq>
        <protein_refseq>NP_056796</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11292</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>3290</gene_start>
        <gene_end>4963</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>mRNA</protein_name>
        <protein_pi>7.51</protein_pi>
        <protein_weight>54466.92</protein_weight>
        <protein_length>524</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|9627197:3290-4963 Rabies virus, complete genome
TAACATCCCTCAAAAGACTCAAGGAAAGATGGTTCCTCAGGCTCTCCTGTTTGTACCCCTTCTGGTTTTT
CCATTGTGTTTTGGGAAATTCCCTATTTACACGATACCAGACAAGCTTGGTCCCTGGAGCCCGATTGACA
TACATCACCTCAGCTGCCCAAACAATTTGGTAGTGGAGGACGAAGGATGCACCAACCTGTCAGGGTTCTC
CTACATGGAACTTAAAGTTGGATACATCTCAGCCATAAAAATGAACGGGTTCACTTGCACAGGCGTTGTG
ACGGAGGCTGAAACCTACACTAACTTCGTTGGTTATGTCACAACCACGTTCAAAAGAAAGCATTTCCGCC
CAACACCAGATGCATGTAGAGCCGCGTACAACTGGAAGATGGCCGGTGACCCCAGATATGAAGAGTCTCT
ACACAATCCGTACCCTGACTACCACTGGCTTCGAACTGTAAAAACCACCAAGGAGTCTCTCGTTATCATA
TCTCCAAGTGTGGCAGATTTGGACCCATATGACAGATCCCTTCACTCGAGGGTCTTCCCTGGCGGGAATT
GCTCAGGAGTAGCGGTGTCTTCTACCTACTGCTCCACTAACCACGATTACACCATTTGGATGCCCGAGAA
TCCGAGACTAGGGATGTCTTGTGACATTTTTACCAATAGTAGAGGGAAGAGAGCATCCAAAGGGAGTGAG
ACTTGCGGCTTTGTAGATGAAAGAGGCCTATATAAGTCTTTAAAAGGAGCATGCAAACTCAAGTTATGTG
GAGTTCTAGGACTTAGACTTATGGATGGAACATGGGTCGCGATGCAAACATCAAATGAAACCAAATGGTG
CCCTCCCGGTCAGTTGGTGAATTTGCACGACTTTCGCTCAGACGAAATTGAGCACCTTGTTGTAGAGGAG
TTGGTCAAGAAGAGAGAGGAGTGTCTGGATGCACTAGAGTCCATCATGACCACCAAGTCAGTGAGTTTCA
GACGTCTCAGTCATTTAAGAAAACTTGTCCCTGGGTTTGGAAAAGCATATACCATATTCAACAAGACCTT
GATGGAAGCCGATGCTCACTACAAGTCAGTCAGAACTTGGAATGAGATCATCCCTTCAAAAGGGTGTTTA
AGAGTTGGGGGGAGGTGTCATCCTCATGTAAACGGGGTATTTTTCAATGGTATAATATTAGGACCTGACG
GCAATGTCTTAATCCCAGAGATGCAATCATCCCTCCTCCAGCAACATATGGAGTTGTTGGTATCCTCGGT
TATCCCCCTTATGCACCCCCTGGCAGACCCGTCTACCGTTTTCAAGAACGGTGACGAGGCTGAGGATTTT
GTTGAAGTTCACCTTCCCGATGTGCACGAACGGATCTCAGGAGTTGACTTGGGTCTCCCGAACTGGGGGA
AGTATGTATTACTGAGTGCAGGGGCCCTGACTGCCTTGATGTTGATAATTTTCCTGATGACATGCTGGAG
AAGAGTCAATCGATCGGAACCTACACAACACAATCTCAGAGGGACAGGGAGGGAGGTGTCAGTCACTCCC
CAAAGCGGGAAGATCATATCTTCATGGGAATCATACAAGAGCGGGGGTGAGACCGGACTGTGAGAGCTGG
CCGTCCTTTCAACGATCCAAGTCCTGAAGATCACCTCCCCTTGGGGGGTTCTTTTTGAAAAAAA</dna_sequence>
        <protein_sequence>>gi|9627201|ref|NP_056796.1| transmembrane glycoprotein G [Rabies virus]
MVPQALLFVPLLVFPLCFGKFPIYTIPDKLGPWSPIDIHHLSCPNNLVVEDEGCTNLSGFSYMELKVGYI
SAIKMNGFTCTGVVTEAETYTNFVGYVTTTFKRKHFRPTPDACRAAYNWKMAGDPRYEESLHNPYPDYHW
LRTVKTTKESLVIISPSVADLDPYDRSLHSRVFPGGNCSGVAVSSTYCSTNHDYTIWMPENPRLGMSCDI
FTNSRGKRASKGSETCGFVDERGLYKSLKGACKLKLCGVLGLRLMDGTWVAMQTSNETKWCPPGQLVNLH
DFRSDEIEHLVVEELVKKREECLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIFNKTLMEADAHYKS
VRTWNEIIPSKGCLRVGGRCHPHVNGVFFNGIILGPDGNVLIPEMQSSLLQQHMELLVSSVIPLMHPLAD
PSTVFKNGDEAEDFVEVHLPDVHERISGVDLGLPNWGKYVLLSAGALTALMLIIFLMTCWRRVNRSEPTQ
HNLRGTGREVSVTPQSGKIISSWESYKSGGETGL</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A glycoprotein G mutant in rabies virus is attenuated. After a one-dose intramuscular vaccination, the ERAg3m virus protected 100% of mice and hamsters from lethal challenge. In co-infections, using a lethal dose of street rabies virus mixed with ERAg3m, 100% of hamsters and 90% of mice survived and were protected against subsequent infection.  [Ref1977:Wu et al., 2011].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene944">
        <gene_name>P protein</gene_name>
        <strain>Flury-HEP</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>291220682</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id>3L32</pdb_id>
        <xrefs>CDD:145910</xrefs>
        <taxonomy_id>11292</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>phosphoprotein</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>297</protein_length>
        <protein_note>Phosphoprotein; pfam03012</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>gi|291220682|gb|ADD84788.1| phosphoprotein [Rabies virus]
MSKIFVNPSAIRAGLADLEMAEETVDLINRNIEDNQAHLQGEPIEVDNLPEDMRQFHLDDEKLSNLGEMV
RVGEGKYREDFQMNEGEDPNLLFQSYLDNVGVQIVRQMRSGERFLKIWSQTVEEIISYVTVNFPNPPGRS
SEDKSTQTTGRELKKETTSILSQRESQPSKAGMVAQVASGPPSLEWSATNEEDDLSVEAEIAHQIAESFS
KKYKFPSRSSGIFLYNFEQLEMNLDDIVKEAKNVPGVTRLAHDGSKIPLRCVLGWVALANSKKFQLLVEA
DKLSKIMQDDLDRYKSC</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A P gene mutant is attenuated in mice and induces significant protection from challenge with wild type Rabies virus [Ref1803:Morimoto et al., 2005].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene648">
        <gene_name>RABVgp1 nucleoprotein N</gene_name>
        <strain>Rabies lyssavirus</strain>
        <vo_id>VO_0011232</vo_id>
        <ncbi_gene_id>1489853</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9627198</ncbi_protein_id>
        <gene_locus_tag>RABVgp1</gene_locus_tag>
        <gene_refseq>M13215</gene_refseq>
        <protein_refseq>NP_056793</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11292</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>58</gene_start>
        <gene_end>1481</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>mRNA</protein_name>
        <protein_pi>6.57</protein_pi>
        <protein_weight>47628.25</protein_weight>
        <protein_length>450</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001542.1:58-1481 Rabies virus, complete genome
TAACACCTCTACAATGGATGCCGACAAGATTGTATTCAAAGTCAATAATCAGGTGGTCTCTTTGAAGCCT
GAGATTATCGTGGATCAATATGAGTACAAGTACCCTGCCATCAAAGATTTGAAAAAGCCCTGTATAACTC
TAGGAAAGGCTCCCGATTTAAATAAAGCATACAAGTCAGTTTTATCATGCATGAGCGCCGCCAAACTTGA
TCCTGACGATGTATGTTCCTATTTGGCGGCGGCAATGCAGTTTTTTGAGGGGACATGTCCGGAAGACTGG
ACCAGCTATGGAATCGTGATTGCACGAAAAGGAGATAAGATCACCCCAGGTTCTCTGGTGGAGATAAAAC
GTACTGATGTAGAAGGGAATTGGGCTCTGACAGGAGGCATGGAACTGACAAGAGACCCCACTGTCCCTGA
GCATGCGTCCTTAGTCGGTCTTCTCTTGAGTCTGTATAGGTTGAGCAAAATATCCGGGCAAAGCACTGGT
AACTATAAGACAAACATTGCAGACAGGATAGAGCAGATTTTTGAGACAGCCCCTTTTGTTAAAATCGTGG
AACACCATACTCTAATGACAACTCACAAAATGTGTGCTAATTGGAGTACTATACCAAACTTCAGATTTTT
GGCCGGAACCTATGACATGTTTTTCTCCCGGATTGAGCATCTATATTCAGCAATCAGAGTGGGCACAGTT
GTCACTGCTTATGAAGACTGTTCAGGACTGGTGTCATTTACTGGGTTCATAAAACAAATCAATCTCACCG
CTAGAGAGGCAATACTATATTTCTTCCACAAGAACTTTGAGGAAGAGATAAGAAGAATGTTTGAGCCAGG
GCAGGAGACAGCTGTTCCTCACTCTTATTTCATCCACTTCCGTTCACTAGGCTTGAGTGGGAAATCTCCT
TATTCATCAAATGCTGTTGGTCACGTGTTCAATCTCATTCACTTTGTAGGATGCTATATGGGTCAAGTCA
GATCCCTAAATGCAACGGTTATTGCTGCATGTGCTCCTCATGAAATGTCTGTTCTAGGGGGCTATCTGGG
AGAGGAATTCTTCGGGAAAGGGACATTTGAAAGAAGATTCTTCAGAGATGAGAAAGAACTTCAAGAATAC
GAGGCGGCTGAACTGACAAAGACTGACGTAGCACTGGCAGATGATGGAACTGTCAACTCTGACGACGAGG
ACTACTTCTCAGGTGAAACCAGAAGTCCGGAAGCTGTTTATACTCGAATCATAATGAATGGAGGTCGACT
GAAGAGATCGCACATACGGAGATATGTCTCAGTCAGTTCCAATCATCAAGCTCGTCCAAACTCATTCGCC
GAGTTTCTAAACAAGACATATTCGAGTGACTCATAAGAAGTTGAATAACAAAATGCCGGAAATCTACGGA
TTGTGTATATCCATCATGAAAAAA

</dna_sequence>
        <protein_sequence>>NP_056793.1 nucleoprotein N [Rabies lyssavirus]
MDADKIVFKVNNQVVSLKPEIIVDQYEYKYPAIKDLKKPCITLGKAPDLNKAYKSVLSCMSAAKLDPDDV
CSYLAAAMQFFEGTCPEDWTSYGIVIARKGDKITPGSLVEIKRTDVEGNWALTGGMELTRDPTVPEHASL
VGLLLSLYRLSKISGQSTGNYKTNIADRIEQIFETAPFVKIVEHHTLMTTHKMCANWSTIPNFRFLAGTY
DMFFSRIEHLYSAIRVGTVVTAYEDCSGLVSFTGFIKQINLTAREAILYFFHKNFEEEIRRMFEPGQETA
VPHSYFIHFRSLGLSGKSPYSSNAVGHVFNLIHFVGCYMGQVRSLNATVIAACAPHEMSVLGGYLGEEFF
GKGTFERRFFRDEKELQEYEAAELTKTDVALADDGTVNSDDEDYFSGETRSPEAVYTRIIMNGGRLKRSH
IRRYVSVSSNHQARPNSFAEFLNKTYSSDS

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Mice vaccinated intraperitoneally (i.p.) with 10^7 p.f.u. of a vaccinia virus recombinant expressing either the glycoprotein (rVac-G) or nucleoprotein (rVac-N) of rabies virus 3 weeks before challenge were protected against peripheral lethal infection [Ref1237:Fujii et al., 1994].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<reference reference_id="reference3281">
		<reference_name>Amann et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Amann R, Rohde J, Wulle U, Conlee D, Raue R, Martinon O, Rziha HJ</authors>
		<title>A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein</title>
		<year>2013</year>
		<volume>87</volume>
		<issue>3</issue>
		<pages>1618-1630</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3278">
		<reference_name>Aspden et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Aspden K, Passmore JA, Tiedt F, Williamson AL</authors>
		<title>Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector</title>
		<year>2003</year>
		<volume>84</volume>
		<issue>Pt 8</issue>
		<pages>1985-1996</pages>
		<journal_book_name>The Journal of general virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference828">
		<reference_name>Brochier et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Brochier B, Kieny MP, Costy F, Coppens P, Bauduin B, Lecocq JP, Languet B, Chappuis G, Desmettre P, Afiademanyo K</authors>
		<title>Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine</title>
		<year>1991</year>
		<volume>354</volume>
		<issue>6354</issue>
		<pages>520-522</pages>
		<journal_book_name>Nature</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference734">
		<reference_name>FDA: Imovax</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: Imovax vaccine information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180097.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference735">
		<reference_name>FDA: Rabavert</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: Rabavert vaccine information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133517.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1237">
		<reference_name>Fujii et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fujii H, Takita-Sonoda Y, Mifune K, Hirai K, Nishizono A, Mannen K</authors>
		<title>Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein</title>
		<year>1994</year>
		<volume>75 ( Pt 6)</volume>
		<issue></issue>
		<pages>1339-1344</pages>
		<journal_book_name>The Journal of general virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3096">
		<reference_name>Jas et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Jas D, Coupier C, Toulemonde CE, Guigal PM, Poulet H</authors>
		<title>Three-year duration of immunity in cats vaccinated with a canarypox-vectored recombinant rabies virus vaccine</title>
		<year>2012</year>
		<volume>30</volume>
		<issue>49</issue>
		<pages>6991-6996</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4968">
		<reference_name>Kang et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kang H, Qi Y, Wang H, Zheng X, Gao Y, Li N, Yang S, Xia X</authors>
		<title>Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus</title>
		<year>2015</year>
		<volume>7</volume>
		<issue>3</issue>
		<pages>1134-1152</pages>
		<journal_book_name>Viruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1236">
		<reference_name>Kaur et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kaur M, Saxena A, Rai A, Bhatnagar R</authors>
		<title>Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice</title>
		<year>2010</year>
		<volume>24</volume>
		<issue>1</issue>
		<pages>173-183</pages>
		<journal_book_name>The FASEB journal : official publication of the Federation of American Societies for Experimental Biology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2380">
		<reference_name>Lodmell et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lodmell DL, Ray NB, Ulrich JT, Ewalt LC</authors>
		<title>DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL)</title>
		<year>2000</year>
		<volume>18</volume>
		<issue>11-12</issue>
		<pages>1059-1066</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference829">
		<reference_name>Mackowiak et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mackowiak M, Maki J, Motes-Kreimeyer L, Harbin T, Van Kampen K</authors>
		<title>Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology</title>
		<year>1999</year>
		<volume>41</volume>
		<issue></issue>
		<pages>571-583</pages>
		<journal_book_name>Advances in veterinary medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference733">
		<reference_name>Manning et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF</authors>
		<title>Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices</title>
		<year>2008</year>
		<volume>57</volume>
		<issue>RR-3</issue>
		<pages>1-28</pages>
		<journal_book_name>MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1803">
		<reference_name>Morimoto et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Morimoto K, Shoji Y, Inoue S</authors>
		<title>Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity</title>
		<year>2005</year>
		<volume>111</volume>
		<issue>1</issue>
		<pages>61-67</pages>
		<journal_book_name>Virus research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2268">
		<reference_name>Osorio et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, Haynes JR, Stinchcomb DT</authors>
		<title>Immunization of dogs and cats with a DNA vaccine against rabies virus</title>
		<year>1999</year>
		<volume>17</volume>
		<issue>9-10</issue>
		<pages>1109-1116</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3215">
		<reference_name>Osorio et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Osorio JE, Frank RS, Moss K, Taraska T, Powell T, Stinchcomb DT</authors>
		<title>Raccoon poxvirus as a mucosal vaccine vector for domestic cats</title>
		<year>2003</year>
		<volume>11</volume>
		<issue>8-10</issue>
		<pages>463-470</pages>
		<journal_book_name>Journal of drug targeting</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference776">
		<reference_name>Rabavert</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>Rabavert Package Insert</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.novartisvaccines.com/downloads/diseases-products/us-pl-rabavert.pdf</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference830">
		<reference_name>Rupprecht et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rupprecht CE, Hanlon CA, Slate D</authors>
		<title>Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control</title>
		<year>2004</year>
		<volume>119</volume>
		<issue></issue>
		<pages>173-184</pages>
		<journal_book_name>Developments in biologicals</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1260">
		<reference_name>Takita-Sonoda et al., 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Takita-Sonoda Y, Fujii H, Mifune K, Ito Y, Hiraga M, Nishizono A, Mannen K, Minamoto N</authors>
		<title>Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection</title>
		<year>1993</year>
		<volume>132</volume>
		<issue>1-2</issue>
		<pages>51-65</pages>
		<journal_book_name>Archives of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference736">
		<reference_name>Wiki: Rabies</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>Wiki: Rabies</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://en.wikipedia.org/wiki/Rabies</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1977">
		<reference_name>Wu et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wu X, Franka R, Henderson H, Rupprecht CE</authors>
		<title>Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies</title>
		<year>2011</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3106">
		<reference_name>Wu et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wu Q, Yu F, Xu J, Li Y, Chen H, Xiao S, Fu ZF, Fang L</authors>
		<title>Rabies-virus-glycoprotein-pseudotyped recombinant baculovirus vaccine confers complete protection against lethal rabies virus challenge in a mouse model</title>
		<year>2014</year>
		<volume>171</volume>
		<issue>1-2</issue>
		<pages>93-9101</pages>
		<journal_book_name>Veterinary microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2162">
		<reference_name>Xiang et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC</authors>
		<title>Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus</title>
		<year>1994</year>
		<volume>199</volume>
		<issue>1</issue>
		<pages>132-140</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3084">
		<reference_name>Xiang et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE</authors>
		<title>Protection of non-human primates against rabies with an adenovirus recombinant vaccine</title>
		<year>2014</year>
		<volume>450-451</volume>
		<issue></issue>
		<pages>243-249</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


